Solid tumours: Building bridges to CAR-T success

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Immunotherapy using chimeric antigen receptor (CAR)-engineered T-cells has achieved remarkable impact in the treatment of selected blood cancers. However, meaningful clinical efficacy against nonhaematological malignancies has largely proven elusive. In this minireview, the main challenges to successful CAR-based intervention against solid tumours are considered. Obstacles are considered in four categories, namely target selection, trafficking of CAR-engineered cells to tumour deposits, the need to overcome the physical, chemical and biological hurdles to immune effector function that operate within the tumour microenvironment and selection of the best host cells for CAR engineering. A range of pre-clinical technologies that have been developed in an effort to overcome these issues are also surveyed. Although clinical progress comes dropping slow, rapid and continued advances in cellular engineering and manufacture, coupled with the emergence of several complementary interventions bodes well for the future success of CAR T-cell immunotherapy of solid tumours.
Original languageEnglish
Article numbere179
Number of pages6
JournalClinical and Translational Discovery
Issue number2
Early online date27 Feb 2023
Publication statusPublished - Apr 2023


Dive into the research topics of 'Solid tumours: Building bridges to CAR-T success'. Together they form a unique fingerprint.

Cite this